Thursday, March 15, 2012

FDA Denies Seroquel Citizen Petition, AstraZeneca Files Suit

On March 7, the Food and Drug Administration (FDA) denied two citizen petitions filed by AstraZeneca September 9 that requested the FDA to require generic versions of its Seroquel antipsychotic (quetiapine) come with warnings about high blood sugar and suicidal tendencies. The FDA denied the requests "without comment," leaving AstraZeneca with no information about the FDA's intentions regarding the generic.

On March 12, AstraZeneca responded by filing a complaint and motion for summary judgment, saying that FDA's nonresponse violated the Administrative Procedure Act and should be set aside. AstraZeneca is asking for an injunction enjoining the FDA from granting final approval for generic versions of Seroquel or its extended form, Seroquel XR. AstraZeneca has argued that the omission of the information in the generic drug's labeling would make a generic product less safe and effective than the branded products. Prior to this action, a generic form of Seroquel was expected to be approved as early as late this month.

Concerns have recently been raised about the use of Seroquel as a sleep aid in soldiers returning from Iraq and Afghanistan. Read more about it in Psychiatric News, here.

(Image: Oliver Sved/




The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.